German (DAX) Life Sciences Industry Analysis

UpdatedMar 09, 2026

DataAggregated Company Financials

Companies6

7D-8.4%
3M-13.7%
1Y-21.3%
YTD-11.9%

Over the last 7 days, the Life Sciences industry has dropped 8.4%, driven by a pullback from SCHOTT Pharma KGaA of 3.9%. In contrast, Gerresheimer has gained 18%. However, the industry is down 21% over the past year. As for the next few years, earnings are expected to grow by 23% per annum.

Industry Valuation and Performance

Has the German Life Sciences Industry valuation changed over the past few years?

Date	Market Cap	Revenue	Earnings	PE	Absolute PE	PS
Mon, 09 Mar 2026	€17.3b	€7.5b	€168.6m	28.1x	102.9x	2.3x
Wed, 04 Feb 2026	€19.8b	€7.5b	€143.5m	37.2x	138.1x	2.6x
Fri, 02 Jan 2026	€19.4b	€7.5b	€143.5m	40.8x	135x	2.6x
Sun, 30 Nov 2025	€20.3b	€7.5b	€143.9m	39.3x	140.9x	2.7x
Tue, 28 Oct 2025	€20.2b	€7.5b	€147.4m	43.5x	136.8x	2.7x
Thu, 25 Sep 2025	€18.5b	€7.4b	€157.8m	22.8x	117.2x	2.5x
Sat, 23 Aug 2025	€18.6b	€7.4b	€157.8m	25.1x	118x	2.5x
Mon, 21 Jul 2025	€19.7b	€7.4b	€99.5m	26x	198.2x	2.7x
Wed, 18 Jun 2025	€20.1b	€7.3b	€114.9m	28.7x	174.8x	2.8x
Fri, 16 May 2025	€21.6b	€7.3b	€114.9m	27.3x	187.9x	3x
Sun, 13 Apr 2025	€17.7b	€7.2b	€125.5m	24.8x	141x	2.5x
Tue, 11 Mar 2025	€21.6b	€7.1b	€156.5m	28.2x	138.3x	3x
Thu, 06 Feb 2025	€23.8b	€7.1b	€169.8m	23.5x	140.1x	3.4x
Sat, 04 Jan 2025	€20.8b	€7.1b	€169.8m	24.5x	122.2x	2.9x
Mon, 02 Dec 2024	€22.0b	€7.1b	€170.5m	27.6x	129.2x	3.1x
Wed, 30 Oct 2024	€24.1b	€7.1b	€171.2m	32x	140.7x	3.4x
Fri, 27 Sep 2024	€24.5b	€7.1b	€172.8m	30.8x	141.5x	3.5x
Sun, 25 Aug 2024	€23.8b	€7.0b	€157.1m	34.2x	151.6x	3.4x
Tue, 23 Jul 2024	€22.7b	€7.0b	€237.1m	35.8x	95.8x	3.2x
Thu, 20 Jun 2024	€21.7b	€7.0b	€333.3m	28.5x	65.2x	3.1x
Sat, 18 May 2024	€26.6b	€7.0b	€340.1m	30x	78.2x	3.8x
Mon, 15 Apr 2024	€32.1b	€7.1b	€385.4m	36.3x	83.3x	4.5x
Wed, 13 Mar 2024	€33.9b	€7.1b	€384.5m	37.2x	88.1x	4.8x
Fri, 09 Feb 2024	€32.5b	€7.3b	€516.3m	37.5x	62.9x	4.4x
Sun, 07 Jan 2024	€30.8b	€7.3b	€507.1m	34.8x	60.7x	4.2x
Tue, 05 Dec 2023	€28.5b	€7.3b	€507.1m	31.4x	56.2x	3.9x
Thu, 02 Nov 2023	€24.8b	€6.4b	€356.1m	37.5x	69.5x	3.9x
Sat, 30 Sep 2023	€26.8b	€6.6b	€498.1m	38.3x	53.8x	4.1x
Mon, 28 Aug 2023	€29.1b	€6.6b	€425.8m	42.5x	68.3x	4.4x
Wed, 26 Jul 2023	€30.2b	€6.8b	€496.6m	39.3x	60.8x	4.5x
Fri, 23 Jun 2023	€27.1b	€6.7b	€487.3m	38.2x	55.5x	4x
Sun, 21 May 2023	€28.1b	€6.7b	€487.3m	38.6x	57.7x	4.2x
Tue, 18 Apr 2023	€30.5b	€6.8b	€595.6m	34.3x	51.2x	4.5x
Thu, 16 Mar 2023	€29.7b	€6.7b	€594.3m	34x	50x	4.4x

Price to Earnings Ratio

50x

Thu, 16 Mar 2023

Current Industry PE

Investors are pessimistic on the German Life Sciences industry, indicating that they anticipate long term growth rates will be lower than they have historically.

The industry is trading at a PE ratio of 103x which is lower than its 3-year average PE of 107x.

The 3-year average PS ratio of 3.5x is higher than the industry's current PS ratio of 2.3x.

Past Earnings Growth

The earnings for companies in the Life Sciences industry have declined 34% per year over the last three years.
Meanwhile revenues for these companies have grown 4.1% per year.
This means that although more sales are being generated, either the cost of doing business or the level of investment back into businesses has increased, which has decreased profits.